FDA Approves ELTROMBOPAG — Hikma Pharmaceuticals USA Inc.
Hikma Pharmaceuticals USA Inc. received FDA approval for its Abbreviated New Drug Application (ANDA) covering oral Eltrombopag Olamine on April 8, 2026, positioning the company to capture market share from branded competitors in the treatment of severe aplastic anemia and related conditions.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day